Premium
Does early treatment improve outcomes in N ‐methyl‐ d ‐aspartate receptor encephalitis?
Author(s) -
Byrne Susan,
McCoy Blathanid,
Lynch Bryan,
Webb David,
King Mary D
Publication year - 2014
Publication title -
developmental medicine and child neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.658
H-Index - 143
eISSN - 1469-8749
pISSN - 0012-1622
DOI - 10.1111/dmcn.12411
Subject(s) - autoimmune encephalitis , encephalitis , medicine , pediatrics , nmda receptor , immunology , receptor , virus
N ‐methyl‐ d ‐aspartate ( NMDA ) receptor encephalitis is a treatable cause of autoimmune encephalitis in both children and adults. It is still unclear if the natural history of the condition in children is altered by early treatment with immunosuppressive therapy. We looked at the outcomes of five children (two males, three females; mean age 6y 9mo, range 4–8y) who were treated empirically for autoimmune encephalitis within a brief period of presentation. Features that led clinicians to suspect autoimmune encephalitis included prominent neuropsychiatric features, movement disorder, seizures, and dysautonomic features. Immunosuppressive therapy was carried out in all cases. In this series of children, in whom the median time from symptom onset to treatment was 5 days and median length of time for follow‐up was 24 months, four out of the five (80%) recovered to their baseline. Early initiation of immunosuppressive therapy may result in improved clinical outcomes.